These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. HIV or zidovudine myopathy? Dalakas M Neurology; 1994 Feb; 44(2):360-1; author reply 362-4. PubMed ID: 8309594 [No Abstract] [Full Text] [Related]
5. [Muscular involvement in human immunodeficiency virus infection]. Laraki R; Lebas J; Baudrimont M; Cabane J; Giral P; Wattiaux MJ; Picard O; Imbert JC Ann Med Interne (Paris); 1990; 141(2):187-92. PubMed ID: 2191617 [No Abstract] [Full Text] [Related]
6. Prognosis in AZT myopathy. Chalmers AC; Greco CM; Miller RG Neurology; 1991 Aug; 41(8):1181-4. PubMed ID: 1714057 [TBL] [Abstract][Full Text] [Related]
7. Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine? Till M; MacDonell KB Ann Intern Med; 1990 Oct; 113(7):492-4. PubMed ID: 1975486 [No Abstract] [Full Text] [Related]
8. Analysis of myopathy in a placebo-controlled zidovudine trial. Simpson DM; Slasor P; Dafni U; Berger J; Fischl MA; Hall C Muscle Nerve; 1997 Mar; 20(3):382-5. PubMed ID: 9052824 [No Abstract] [Full Text] [Related]
9. Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine. Manji H; Harrison MJ; Round JM; Jones DA; Connolly S; Fowler CJ; Williams I; Weller IV J Neurol; 1993 Sep; 240(8):479-88. PubMed ID: 8263554 [TBL] [Abstract][Full Text] [Related]
10. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions. Lane RJ; McLean KA; Moss J; Woodrow DF Neuropathol Appl Neurobiol; 1993 Oct; 19(5):406-13. PubMed ID: 8278024 [TBL] [Abstract][Full Text] [Related]